Regarding the ASA classification, in the three t‐CEA expression groups (+, ++, +++), 371 patients had stage I CRC [116 (76.8%), 144 (71.3%), and 111 (67.7%)]; 133 patients had stage II CRC [31 (20.5%), 53 (26.2%), and 49 (29.9%)]; and 13 patients had stage III [4 (2.6%), 5 (2.5%), and 4 (2.4)], respectively; no significant differences were observed (P = 0.456). The gene discussed is CEACAM5; the disease is colorectal carcinoma.